Net Income

Facing a critical cash shortfall, Cue Biopharma turns to the market, betting its promising cancer and autoimmune pipeline can win over investors.

An executive order accelerates moving cannabis to Schedule III, promising massive tax breaks for businesses but leaving advocates wanting more federal reform.

Facing financial headwinds, Celularity lands a critical $12M from a top investor to push its ambitious anti-aging and regenerative therapies forward.

National homebuilder Toll Brothers opens Bethany Farms in Simpsonville, tapping into the area's hot luxury market with customizable homes and amenities.

A simple, low-cost heart pill may hold the key to treating Alzheimer's and kidney disease. CardioPharma is now funding research to unlock its potential.

Millions struggle to swallow pills. Azurity's new FDA-approved liquid hypertension drug, Javadin, offers a ready-to-use solution for better adherence.

European FinTech Multitude AG unveils its 2026 financial calendar, offering investors a clear roadmap amid strong growth and evolving market dynamics.

Medical cannabis firm Crucial Innovations retains FOCUS Capital Partners, signaling a push for institutional investment and a potential 2026 US listing.

A new report projects a staggering $47T cost from chronic illness by 2039. Experts say prevention and innovation could save trillions and 13.5M lives.

Syra Health appoints Gregory R. Alexander as CEO, banking on his military discipline and record of scaling healthcare firms to drive its next growth phase.

Formerly a green housing developer, the company is now RenX Enterprises, betting its future on the multi-billion dollar market for sustainable soils.

Facing market pressure, Mobileye plans a major CES 2026 reveal of its 'physical AI' and new chip architecture alongside key partner Volkswagen.

The AI defense firm's stock surged after announcing a share repurchase, a move reflecting deep internal confidence amid a booming defense-tech market.

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

Dynatrace becomes a launch partner for Google's Gemini, embedding advanced observability directly into the next generation of agentic AI for developers and enterprises.

Avantor appoints financial heavyweight Simon Dingemans to its board, a strategic move to accelerate its ambitious turnaround amid market pressures.

Newly public AI firm Fusemachines unveils an ambitious 2026 growth plan, but faces significant financial hurdles and deep investor skepticism.

A new alliance led by engineering giant AtkinsRéalis will deliver the Midlands Rail Hub, a project promising vast economic growth and 300 extra trains daily.

Vancouver-based TRUBAR agrees to a C$201M buyout by Turkish food conglomerate ETİ Gıda, marking a major move in the booming plant-based snack market.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.